Placental drug disposition and its clinical implications

被引:0
|
作者
Weier, Naomi [2 ]
He, Shu-Ming [1 ]
Li, Xiao-Tian [3 ]
Wang, Lin-Lin [4 ,5 ]
Zhou, Shu-Feng [4 ]
机构
[1] Xiaolan Peoples Hosp, Dept Obstet & Genecol, Zhongshan, Guangdong, Peoples R China
[2] Queensland Univ Technol, Sch Life Sci, Div Pharma, Brisbane, Qld, Australia
[3] Fudan Univ, Obstet & Gynecol Hosp, Dept Maternal Med, Shanghai 200433, Peoples R China
[4] RMIT Univ, WHO Collaborating Ctr Tradit Med, Sch Hlth Sci, Div Chinese Med, Melbourne, Vic, Australia
[5] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100083, Peoples R China
关键词
placenta; drug metabolism; drug transporter; cytochrome P450; P-glycoprotein;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The placenta is a unique organ that is essential to a healthy and normal pregnancy. A number of phase I and II metabolizing enzymes are expressed at moderate levels in the placenta, and have been proven to have the ability to metabolize certain xenobiotics. Depending on the substrate, this metabolic action may have significant clinical implications on how it affects the fetus. A wide variety of transporters including P-glycoprotein, breast cancer resistance protein, and multidrug resistance associated proteins have also been discovered in the placenta, and while most are found to have mainly physiological substrates, there are a number of xenobiotics which are also able to gain access to the fetus through transport across the placenta. Depending on the xenobiotics and its intended action, drug transport across the placenta may be desired, acceptable or undesirable. Medications administered to the mother but designed to work on the fetus are now being used increasingly, and demonstrates an important clinical implication in which drug transport across the placenta is desirable. However, medications designed to treat the mother but are also able to cross the placenta carry potential risks to damage the developing fetus, and it is therefore essential that the effects of different drugs on the fetus are known before they are administered during pregnancy. There is still much unknown about drug transport and drug metabolism in the placenta, and it is vital that in the future further research is done to discover the clinical implications of these activities in the placenta. This research is often complicated by the fact that it is unethical to run studies in pregnant women, and so research is often carried out in pregnant animals. These results are not always accurate, however, as the human's placental structure is different from the placenta in other animals. Drug metabolism and drug transport across the placenta should continue to be researched, and guidelines need to be developed to ensure that any medications used during pregnancy are safe to both the mother and the fetus, and that successful treatment of the medical condition is carried out.
引用
收藏
页码:106 / 121
页数:16
相关论文
共 50 条
  • [31] CLINICAL RELEVANCE OF EFFECT OF HEPATIC DISEASE ON DRUG DISPOSITION
    BOND, WS
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1978, 35 (04): : 406 - 414
  • [32] Clinical Trial Design and Alterations in Drug Disposition with Age
    Michael L. Christensen
    Russell W. Chesney
    Richard A. Helms
    Drug information journal : DIJ / Drug Information Association, 2000, 34 : 157 - 163
  • [33] Clinical trial design and alterations in drug disposition with age
    Christensen, ML
    Chesney, RW
    Helms, RA
    DRUG INFORMATION JOURNAL, 2000, 34 (01): : 157 - 163
  • [35] Prediction of Drug Disposition on the Basis of its Chemical Structure
    David Stepensky
    Clinical Pharmacokinetics, 2013, 52 : 415 - 431
  • [36] STREET DRUG ANALYSIS AND ITS SOCIAL AND CLINICAL IMPLICATIONS - MARSAMAN,JA
    COSPER, R
    CANADIAN REVIEW OF SOCIOLOGY AND ANTHROPOLOGY-REVUE CANADIENNE DE SOCIOLOGIE ET D ANTHROPOLOGIE, 1977, 14 (02): : 263 - 264
  • [37] DRUG-ABUSE AND ITS CLINICAL IMPLICATIONS WITH SPECIAL REFERENCE TO NIGERIA
    ABIODUN, OA
    CENTRAL AFRICAN JOURNAL OF MEDICINE, 1991, 37 (01) : 24 - &
  • [39] Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline
    Flarakos, Jimmy
    Du, Yancy
    Gu, Helen
    Wang, Lai
    Einolf, Heidi J.
    Chun, Dung Y.
    Zhu, Bing
    Alexander, Natalia
    Natrillo, Adrienne
    Hanna, Imad
    Ting, Lillian
    Zhou, Wei
    Dole, Kiran
    Sun, Haiying
    Kovacs, Steven J.
    Stein, Daniel S.
    Tanaka, S. Ken
    Villano, Stephen
    Mangold, James B.
    XENOBIOTICA, 2017, 47 (08) : 682 - 696
  • [40] Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: Pharmacological and toxicological implications
    Fimognari, C.
    Lenzi, M.
    Hrelia, P.
    CURRENT DRUG METABOLISM, 2008, 9 (07) : 668 - 678